Amyloidosis Pipeline Drugs Assessment: Clinical Trails Analysis, Player ProfilesPosted by saikrishna on May 29th, 2018 Amyloidosis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018 Amyloidosis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018 Amyloidosis Pipeline Drugs AssessmentOverview: Amyloidosis is a rare disease, which occurs due to deposition of amyloid in organs. It is an abnormal protein, produced in the bone marrow and accumulates at any part of the tissue or organ. Amyloidosis may affect different parts of the body in different people. Amyloidosis affects heart, kidney, liver, spleen and nervous system. Amyloidosis is diagnosed with the laboratory tests by identifying the abnormality in the protein in blood and urine. Furthermore, imaging techniques and biopsy may be performed to diagnose the disease and presence of amyloidosis. Treatment is given to relive the symptoms and limit the further production of amyloid. Treatment depends on the type of amyloidosis. Chemotherapeutic agents are used to treat the immunoglobulin light chain amyloidosis and therapies may include autologous blood stem cell transplant. AA amyloidosis is treated by treating underlying condition for example, anti inflammatory drugs for treating rheumatoid arthritis. For Hereditary amyloidosis, liver transplant may be an option. A sample of this report is available upon request @ Segmentation: Amyloidosis pipeline drugs are segmented based on route of administration, trial phase,and company By type, Amyloidosis pipeline drugs are segmented into
By trial phase, Amyloidosis pipeline drugs are segmented into
By company, Amyloidosis pipeline drugs are segmented into
Like it? Share it! More by this author |